ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2019
Negative CT Contrast Agents for the Diagnosis of Malignant Osteosarcoma.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- Theranostics: a multifaceted approach utilizing nano-biomaterials.Discover nano · 2024Review
- Fusing Positive and Negative CT Contrast Nanoagent for the Sensitive Detection of Hepatoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Imaging evaluation of blood supply changes after chemotherapy of osteosarcoma and its correlation with tumor necrosis rate.Journal of bone oncology · 2023Article
- A novel CEST-contrast nanoagent for differentiating the malignant degree in breast cancer.RSC advances · 2023Article
- Machine Learning-Based Prediction of Lymph Node Metastasis Among Osteosarcoma Patients.Frontiers in oncology · 2022Article
- Biomaterials for Orthopaedic Diagnostics and Theranostics.Current opinion in biomedical engineering · 2021Article
- Harnessing X-Ray Energy-Dependent Attenuation of Bismuth-Based Nanoprobes for Accurate Diagnosis of Liver Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma.Biosensors · 2021Review
- Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response.Cancer drug resistance (Alhambra, Calif.) · 2021Article
- Understanding the in vivo Fate of Advanced Materials by Imaging.Advanced functional materials · 2020Article
- Enhancing the Efficacy of Metal-Free MRI Contrast Agents via Conjugating Nitroxides onto PEGylated Cross-Linked Poly(Carboxylate Ester).Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- A Nanostrategy for Efficient Imaging-Guided Antitumor Therapy through a Stimuli-Responsive Branched Polymeric Prodrug.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Mesoporous Silica Nanoparticles for the Treatment of Complex Bone Diseases: Bone Cancer, Bone Infection and Osteoporosis.Pharmaceutics · 2020Review
- Negative CT Contrast Agents for the Diagnosis of Malignant Osteosarcoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current positive computed tomography (CT) contrast agents (PCTCAs) including clinical iodides, present high CT density value (CT-DV). However, they are incapable for the accurate diagnosis of some diseases with high CT-DV, such as osteosarcoma. Because bones and PCTCAs around osteosarcoma generate similar X-ray attenuations. Here, an innovative strategy of negative CT contrast agents (NCTCAs) to reduce the CT-DV of osteosarcoma is proposed, contributing to accurate detection of osteosarcoma. Hollow mesoporous silica nanoparticles, loading ammonia borane molecules and further modified by polyethylene glycol, are synthesized as NCTCAs for the diagnosis of osteosarcoma. The nanocomposites can produce H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.